The UK company Fertility Focus and its product Ovusense is said to deliver a 99% accuracy in predicting ovulation. The company states that 30% of women have ovulatary issues – most of which are difficult to discern. They also state that over 50% of women are unable to conceive within the first 12 months of trying. They believe their “real time” ovulation product is far superior to anything on the market and they are looking to raise up to £500,000 on SyndicateRoom. The offer has already raised £340,000 with pre-money valuation placed at just over £4 million. The funding is scheduled to close on Sunday, July 12th.
Fertility Focus sees a market that number 17 million women – each year. The product has all the required regulatory approvals and has entered both the European and US markets via an e-commerce site.
So what will the new capital be used to accomplish? Marketing. OvuSense as a new product entry requires funding to generate brand awareness. Fertility Focus also states the new funding will be used to complete the next generation of their product.
Fertility Focus Chairman, Steve Godber, sees success as a foregone conclusion, “It is not a matter of whether Fertility Focus will deliver a return to shareholders, it is just a question of when and how much,” he says with certainty.
The company believes their strategy “will lead to an exit value in excess of £60 million from the current valuation of £ 4 million, and will give investors in this round a greater than 10x return on their investment.. ”
The lead investor on this round is Christine Soden, CFO of EGI, a US based MedTech company that is publicly traded on AIM. She is also on the Fertility Focus Board of Directors. She is joined by Adrian Cassidy, a corporate coach at Mackie Consulting as well as a Coach at GrowthAccelerator in Cambridge.
“I came across Fertility Focus on SyndicateRoom last year. I’ve been very lucky and had 6 children. But, seeing how much difficulty some of my friends have had getting pregnant, I have become very aware of the troubles many couples have. For that reason I was attracted to the company both because of the help it can provide to people who are struggling to get pregnant and because it could be a very good investment.”
Adrian says that OvuSense is getting traction and the next gen product should be available in 2016.
“This is a rare opportunity to invest in a proven product with strong sales traction and a robust global growth strategy. The team has world-class expertise in consumer digital marketing, high-volume medical devices, women’s health and intellectual property development. The CEO, chairman and lead angel investor each have several successful sector exits behind them.” states Goncalo De Vasconcelos, CEO and co-founder at SyndicateRoom.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!